IE911971A1 - Treatment of disease - Google Patents

Treatment of disease

Info

Publication number
IE911971A1
IE911971A1 IE197191A IE197191A IE911971A1 IE 911971 A1 IE911971 A1 IE 911971A1 IE 197191 A IE197191 A IE 197191A IE 197191 A IE197191 A IE 197191A IE 911971 A1 IE911971 A1 IE 911971A1
Authority
IE
Ireland
Prior art keywords
use according
compound
substituent
formula
phenyl
Prior art date
Application number
IE197191A
Other languages
English (en)
Original Assignee
Fmc Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fmc Corp filed Critical Fmc Corp
Publication of IE911971A1 publication Critical patent/IE911971A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IE197191A 1990-06-11 1991-06-10 Treatment of disease IE911971A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53579490A 1990-06-11 1990-06-11

Publications (1)

Publication Number Publication Date
IE911971A1 true IE911971A1 (en) 1991-12-18

Family

ID=24135791

Family Applications (1)

Application Number Title Priority Date Filing Date
IE197191A IE911971A1 (en) 1990-06-11 1991-06-10 Treatment of disease

Country Status (7)

Country Link
AU (1) AU8185491A (pt)
CS (1) CS176291A3 (pt)
IE (1) IE911971A1 (pt)
IL (1) IL98405A0 (pt)
PT (1) PT97937A (pt)
WO (1) WO1991019418A1 (pt)
ZA (1) ZA914435B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW492975B (en) * 1993-07-26 2002-07-01 Novartis Ag Tryptase inhibitor
US5767373A (en) 1994-06-16 1998-06-16 Novartis Finance Corporation Manipulation of protoporphyrinogen oxidase enzyme activity in eukaryotic organisms
US5939602A (en) * 1995-06-06 1999-08-17 Novartis Finance Corporation DNA molecules encoding plant protoporphyrinogen oxidase and inhibitor-resistant mutants thereof
US6023012A (en) * 1996-02-28 2000-02-08 Novartis Finance Corporation DNA molecules encoding plant protoporphyrinogen oxidase
US6084155A (en) * 1995-06-06 2000-07-04 Novartis Ag Herbicide-tolerant protoporphyrinogen oxidase ("protox") genes
PL328617A1 (en) * 1996-02-28 1999-02-01 Novartis Ag Promotors of protoporphyrinogen oxidase genes residing in plants
CN103694243B (zh) * 2013-12-20 2015-09-09 中国农业大学 2-取代吡啶基-1,2,4-三唑并[1,2-a]哒嗪化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU190371B (en) * 1980-12-18 1986-08-28 The Wellcome Foundation Ltd,Gb Process for producing ether-type compounds and pharmaceutical compositions containing them as active agents
CA1192545A (en) * 1982-02-16 1985-08-27 Glaxo Group Limited Heterocyclic derivatives as histamine h.sub.2- antagonists
US5025029A (en) * 1986-10-10 1991-06-18 Children's Hospital Medical Center Of Northern California Method for augmenting fetal hemoglobin
US4820722A (en) * 1987-08-14 1989-04-11 Eli Lilly And Company Disubstituted tetrazoles and their use as leukotriene antagonists
US4847276A (en) * 1988-09-06 1989-07-11 Merrell Dow Pharmaceuticals Inc. Treatment of thromobocytosis with 5-(4-chlorophenyl)-2,4-diemthyl-3H-1,2,4-triazole-3-thione

Also Published As

Publication number Publication date
AU8185491A (en) 1992-01-07
IL98405A0 (en) 1992-07-15
CS176291A3 (en) 1992-08-12
PT97937A (pt) 1992-04-30
ZA914435B (en) 1992-03-25
WO1991019418A1 (en) 1991-12-26

Similar Documents

Publication Publication Date Title
US5407808A (en) Method and composition for photodynamic treatment and detection of tumors
US5298502A (en) Method and composition for photodynamic treatment and detection of tumors
AU633537B2 (en) Use of certain herbicides in cancer treatment and production of protoporphyrin ix
Clarkson The pharmacology of mercury compounds
Costantino et al. Pharmacological approaches to the treatment of diabetic complications
US6133322A (en) Quinone derivatives for treating or preventing diseases associated with iron overload
SHUKLA et al. Glutathione peroxidase and catalase in liver, kidney, testis and brain regions of rats following cadmium exposure and subsequent withdrawal
Bevan et al. In vivo insulin mimetic effects of pV compounds: role for tissue targeting in determining potency
Büyükokuroğlu et al. Dantrolene may prevent organophosphate-induced oxidative stress and muscle injury
IE911971A1 (en) Treatment of disease
Fornstedt et al. Vitamin C deficiency facilitates 5‐S‐cysteinyldopamine formation in guinea pig striatum
Böni et al. Tin-mesoporphyrin inhibits heme oxygenase activity and heme-iron absorption in the intestine
Senthil et al. Lipid peroxidation and antioxidants status in patients with papillary thyroid carcinoma in India.
Manzione et al. Development of porphyria cutanea tarda after treatment with cyclophosphamide
Sieber et al. Effects of hycanthone on rapidly proliferating cells
Macdonald et al. Iron deficiency anemia: mitochondrial α-glycerophosphate dehydrogenase in guinea pig skeletal muscle
RU2074719C1 (ru) Способ разрушения опухолевых клеток млекопитающих и фармацевтическая композиция для разрушения опухолевых клеток млекопитающих
Hiroyoshi et al. Decreased erythrocyte δ-aminolevulinate dehydratase activity after styrene exposure
Gumieniczek Oxidative stress in kidney and liver of alloxan-induced diabetic rabbits: effect of repaglinide
Alter et al. Inhibition of hemoglobin synthesis by cyanate in vitro
HRP930762A2 (en) Preparation and use of porphyrin
Lin et al. CYTOPROTECTION AGAINST MEROCYANINE 540‐SENSITIZED PHOTOINACTIVATION OF THE Na+, K+‐ADENOSINE TRIPHOSPHATASE IN LEUKEMIA CELLS: GLUTATHIONE AND SELENOPEROXIDASE INVOLVEMENT
AU2003213027A1 (en) Therapeutic and prophylactic treatment of aging and disorders of aging in humans
Sen et al. Interaction of ascorbate and α-tocopherol enhances antioxidant reserve of erythrocytes during anemia in visceral leishmaniasis
Ziman et al. The effect of fluroxene [(2, 2, 2-trifluoroethoxy) ethane] on haem biosynthesis and degradation